Interferon-beta (N: 7), glatiramer acetate (N: 5), dimethyl fumarate (N: 2), and ocrelizumab (N: 2) were used for the treatment of the MS patients who were later diagnosed with cancer. Here, IFNB1 is linked to myeloid sarcoma.